Benitec Biopharma Inc. (BNTC)
| Market Cap | 18.89M |
| Revenue (ttm) | 48,000 |
| Net Income (ttm) | n/a |
| Shares Out | 4.30M |
| EPS (ttm) | -5.80 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 24 |
| Last Price | $3.96 |
| Previous Close | $3.75 |
| Change ($) | 0.21 |
| Change (%) | 5.60% |
| Day's Open | 3.84 |
| Day's Range | 3.70 - 4.27 |
| Day's Volume | 915,630 |
| 52-Week Range | 2.52 - 17.39 |
HAYWARD, Calif., Dec. 7, 2020 /PRNewswire/ -- Benitec Biopharma, Inc. (NASDAQ: BNTC), today announced that its 2020 Annual Meeting of Stockholders will be held virtually on Wednesday December ...
HAYWARD, Calif., Oct. 6, 2020 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing no...
HAYWARD, Calif., Oct. 2, 2020 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing no...
HAYWARD, Calif., Sept. 23, 2020 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing ...
HAYWARD, Calif., Sept. 1, 2020 /PRNewswire/ -- Benitec Biopharma, Inc.
HAYWARD, Calif., July 8, 2020 /PRNewswire/ -- Benitec Biopharma, Inc. (NASDAQ: BNTC), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based ...
Penny stocks can be dangerous, particularly in this economic environment – so quick thinking and stop losses will be your best friends.
About BNTC
Benitec Biopharma, a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.
| Industry Biotechnology | Founded 1995 |
| CEO Dr. Jerel A. Banks Ph.D., M.D. | Employees 14 |
| Stock Exchange NASDAQ | Ticker Symbol BNTC |